La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Dermata Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Dermata Therapeutics..

Dermata Therapeutics (NASDAQ:DRMA) Azioni, Quote.MetaTitle.option-chain

Dermata Therapeutics

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics Inc

Aditxt

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

Bone Biologics

BriaCell Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

BioVie

Celularity

Estrella Immunopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Lixte Biotechnology Holdings, Inc. - Warrants

Lixte Biotechnology

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Sunshine Biopharma

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Silexion Therapeutics

Surrozen

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Dermata Therapeutics (DRMA) Previsione

Notizie

Utili

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Comments

Dermata Therapeutics Catena di Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO